Published in J Natl Med Assoc on September 01, 2002
Race, ethnic group, and clinical research. BMJ (2003) 1.43
Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail (2009) 1.12
Views on personalized medicine: do the attitudes of African American and white prescription drug consumers differ? Public Health Genomics (2009) 0.93
Grassroots marketing in a global era: more lessons from BiDil. J Law Med Ethics (2011) 0.79
Limitations of the use of clinical trial results in managing heart failure in the African-American community: a time for active participation in generating applicable data. J Natl Med Assoc (2003) 0.75
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 6.58
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med (2001) 5.30
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med (2001) 4.07
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Racial profiling in medical research. N Engl J Med (2001) 3.25
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr (2000) 2.96
Racial disparities in medical care. N Engl J Med (2001) 2.58
Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis (1995) 2.02
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail (1999) 1.96
Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J (1999) 1.82
Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol (2001) 1.81
Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest (1996) 1.46
Minority recruitment in clinical trials: a conference at Tuskegee, researchers and the community. Ann Epidemiol (2000) 1.43
Is the prognosis of heart failure improving? J Am Coll Cardiol (2000) 1.29
Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension (1998) 1.26
Brachial vascular reactivity in blacks. Hypertension (2000) 1.23
Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. Am J Cardiol (1998) 1.20
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail (2002) 1.11
Racial differences in hemodynamic responses to environmental thermal stress among adolescents. Circulation (2000) 1.00
Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation (1991) 0.98
Ischemic stroke outcome: racial differences in the trial of danaparoid in acute stroke (TOAST). Neurology (2001) 0.90
Building a gateway to promote cardiovascular health research in African American communities: lessons and findings from the field. Am J Med Sci (2001) 0.82
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation (2002) 2.35
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol (2008) 2.17
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (2003) 2.10
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J (2004) 2.09
C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation (2005) 1.92
Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail (2003) 1.77
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail (2013) 1.61
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol (2002) 1.58
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail (2004) 1.57
Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation (2004) 1.56
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol (2006) 1.54
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol (2007) 1.49
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J (2005) 1.46
Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep (2007) 1.46
Identifying early cardiovascular disease to target candidates for treatment. J Clin Hypertens (Greenwich) (2008) 1.41
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation (2010) 1.39
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation (2011) 1.35
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2002) 1.34
Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens (2003) 1.27
Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life. J Card Fail (2006) 1.22
Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail (2003) 1.21
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol (2004) 1.18
Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation (2006) 1.15
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation (2005) 1.14
Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail (2009) 1.12
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail (2002) 1.11
Determinants of radial artery pulse wave analysis in asymptomatic individuals. Am J Hypertens (2004) 1.11
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation (2009) 1.10
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail (2007) 1.07
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail (2013) 1.04
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol (2006) 1.03
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med (2006) 1.03
Monitoring vascular health beyond blood pressure. Curr Hypertens Rep (2006) 1.01
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol (2002) 0.99
Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol (2002) 0.98
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail (2006) 0.98
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail (2007) 0.97
Prognostic application of arterial stiffness: task forces. Am J Hypertens (2002) 0.97
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail (2008) 0.94
Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. Eur J Heart Fail (2006) 0.93
Acceptability and psychometric properties of the Minnesota Living With Heart Failure Questionnaire among patients undergoing heart valve surgery: validation and comparison with SF-36. J Card Fail (2008) 0.91
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. Am Heart J (2012) 0.91
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail (2010) 0.90
Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. J Card Fail (2009) 0.90
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation (2005) 0.88
Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. J Am Soc Hypertens (2010) 0.88
Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction. J Card Fail (2003) 0.87
Clinical and analytical considerations in the study of health status in device trials for heart failure. J Card Fail (2005) 0.87
Definition and classification of hypertension: an update. J Clin Hypertens (Greenwich) (2009) 0.86
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail (2013) 0.86
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail (2005) 0.84
Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) (2004) 0.84
Endothelial dysfunction and the metabolic syndrome. Curr Diab Rep (2003) 0.83
Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail (2015) 0.82
The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. Arch Sex Behav (2002) 0.82
Arguments prove nothing unless verified. A commentary on Kaufman's "Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example". Soc Sci Med (2008) 0.81
Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol (2006) 0.81
Myocardial structural effects of aldosterone receptor antagonism in heart failure. J Am Coll Cardiol (2007) 0.81
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. Clin Pharmacokinet (2007) 0.80
Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. Congest Heart Fail (2007) 0.80
Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol (2007) 0.80
Monitoring adherence to guidelines. Circ Heart Fail (2008) 0.80
Detecting the patient at risk of heart failure. J Am Coll Cardiol (2010) 0.79
Calculated plasma volume status and prognosis in chronic heart failure. Eur J Heart Fail (2014) 0.78
Beta-blocker dosing in community-based treatment of heart failure. Am Heart J (2007) 0.78
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J (2004) 0.78
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail (2008) 0.78
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail (2010) 0.78
Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. J Card Fail (2012) 0.77
Sympathetic nervous system in heart failure. Circulation (2002) 0.77
Pharmacotherapy: inhibiting LV remodeling—the need for a targeted approach. Nat Rev Cardiol (2011) 0.77
Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. J Am Soc Hypertens (2011) 0.77
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. Am J Cardiovasc Drugs (2007) 0.76
Remodeling as an end-point in heart failure therapy. Cardiovasc Drugs Ther (2004) 0.76
Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial. Am J Cardiovasc Drugs (2004) 0.76
Measuring endothelial function. Curr Diab Rep (2006) 0.76
Inotropic therapy for heart failure: paradise lost. Eur Heart J (2009) 0.76
Blood pressure and the therapy of advanced heart failure. J Am Coll Cardiol (2004) 0.75
Measuring endothelial dysfunction. J Hypertens (2007) 0.75
B-type natriuretic peptide and artery stiffness. Am J Hypertens (2006) 0.75
Is activation of the renin-angiotensin system hazardous to your health? Eur Heart J (2011) 0.75